Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia

BACKGROUND: Hyponatremia (serum sodium concentration, <135 mmol per liter) is a predictor of death among patients with chronic heart failure and cirrhosis. At present, therapy for acute and chronic hyponatremia is often ineffective and poorly tolerated. We investigated whether tolvaptan, an orally a... View More